Research Topics
| D MahadevanSummaryAffiliation: University of Arizona Country: USA Publications
| Collaborators
|
Detail Information
Publications
Tumor-stroma interactions in pancreatic ductal adenocarcinomaDaruka Mahadevan
Hematology Oncology, The University of Arizona Cancer Center, 1515 North Campbell Avenue, Tucson, AZ 58724, USA
Mol Cancer Ther 6:1186-97. 2007..This review summarizes our current understanding of the mechanisms that potentially drive the DR in PDA and future possibilities for therapeutic targeting of this critical process...
Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350Daruka Mahadevan
Section of Hematology, University of Arizona Arizona Cancer Center, Tucson, Arizona 85724, USA
Cancer 119:371-9. 2013..Gemcitabine was included because of its excellent single-agent activity in PTCL...
Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphomaDaruka Mahadevan
Arizona Cancer Center, The University of Arizona, Tucson, Arizona 85724, USA
Clin Cancer Res 18:2210-9. 2012..The addition of rituximab [R] to MV or MD was evaluated for synthetic lethality...- The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cellsJames W Welsh
Departmentr of Radiation Oncology, The University of Texas M, d, Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, USA
Radiat Oncol 4:69. 2009..We hypothesized that inhibiting c-Met would decrease this protection and thus sensitize resistant tumor cells to the effects of radiation therapy... - MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancerWenqing Qi
Arizona Cancer Center, The University of Arizona, Tucson, AZ 85724, USA
BMC Cancer 9:142. 2009..In this study, we evaluate whether MP470, a novel receptor tyrosine kinase inhibitor alone or in combination with Erlotinib has inhibitory effect on prostate cancer in vitro and in vivo... - Transcriptosome and serum cytokine profiling of an atypical case of myelodysplastic syndrome with progression to acute myelogenous leukemiaDaruka Mahadevan
University of Arizona Cancer Center, Tucson, Arizona 85724, USA
Am J Hematol 81:779-86. 2006..Hence, a biomics approach has provided insight into elucidating disease mechanisms, molecular prognostic factors, and discovery of novel targets for therapeutic intervention... - Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signaturesDaruka Mahadevan
Department of Medicine, Arizona Cancer Center, University of Arizona, 1515 North Campbell Avenue, Tucson, AZ 85724, USA
Mol Cancer Ther 4:1867-79. 2005..This study illustrates the relevance of tumor-stroma immune trafficking and identified potential novel prognostic markers and targets for therapeutic intervention... - Phase I study of fixed dose gemcitabine plus epirubicin in patients with advanced solid malignanciesDaruka Mahadevan
Arizona Cancer Center, University of Arizona Health Sciences Center, Tucson, Arizona, USA
Am J Clin Oncol 32:607-11. 2009..The study was designed based on the hypothesis that prolonged exposure (over 90 minutes) may improve response rates and combination with epirubicin (EPI) is synergistic... - A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumorsD Mahadevan
Arizona Cancer Center, Tucson, AZ 85724, USA
Ann Oncol 22:2137-43. 2011..Based on potent antitumor activity in preclinical models, a first-in-human clinical trial in refractory solid tumors investigated its safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD)... - Novel therapeutics for aggressive non-Hodgkin's lymphomaDaruka Mahadevan
Arizona Cancer Center, Tucson, AZ, USA
J Clin Oncol 29:1876-84. 2011..Furthermore, we have developed the concept of a therapeutic signature using the 10 hallmarks of cancer, which may be incorporated into novel phase I/II drug development programs... - Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategiesDaruka Mahadevan
University of Arizona Cancer Center, Tucson, AZ 85724, USA
Blood 104:1940-51. 2004..Lessons learned from investigations of these and other mechanisms of cellular defense hold promise for a renaissance in the development of targeted therapeutics in acute leukemia... - Structure-based design of novel anti-cancer agents targeting aurora kinasesDaruka Mahadevan
Arizona Cancer Center, Division of Hematology Oncology and Division of Medicinal Chemistry, University of Arizona, 1515, N Campbell Avenue, Tucson, AZ 85724, USA
Curr Med Chem Anticancer Agents 3:25-34. 2003..In this review, we discuss the biology, rationale for targeting and approaches taken to inhibit this family of protein kinases, implicated in dysregulated chromosome segregation and cytokinesis... - A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumorsD Mahadevan
Arizona Cancer Center, Tucson, AZ 85724, USA
Oncogene 26:3909-19. 2007..MP470 synergizes with docetaxel (taxotere) and is cytotoxic to GIST cells... - In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316Emmanuelle J Meuillet
Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA
Oncol Res 14:513-27. 2004..Thus, PX-316 is the lead compound of a new class of potential agents that inhibit Akt survival signaling... - Discovery of a novel class of AKT pleckstrin homology domain inhibitorsDaruka Mahadevan
College of Medicine, Arizona Cancer Center, University of Arizona, Tucson, AZ 85721 0038, USA
Mol Cancer Ther 7:2621-32. 2008..These results show that these compounds are the first small molecules selectively targeting the PH domain of AKT... - Targeting aurora2 kinase in oncogenesis: a structural bioinformatics approach to target validation and rational drug designHariprasad Vankayalapati
Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724, USA
Mol Cancer Ther 2:283-94. 2003.... - A conserved glutamate residue in transmembrane helix 10 influences substrate specificity of rabbit OCT2 (SLC22A2)Xiaohong Zhang
Department of Physiology, University of Arizona, Tucson, Arizona 85724, USA
J Biol Chem 280:34813-22. 2005..The results suggest that homology modeling offers an opportunity to direct future site-directed studies of OCT/substrate interaction... - Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignanciesD Mahadevan
University of Arizona Cancer Center, Tucson, AZ, USA
Eur J Cancer 48:3319-27. 2012..A first-in-human study evaluated safety, dose limiting toxicities (DLT), maximum tolerated dose (MTD), pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of SF1126, in patients with advanced solid and B-cell malignancies... - Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approachSteven L Warner
College of Pharmacy, University of Arizona, Tucson, Arizona, USA
Mol Cancer Ther 5:1764-73. 2006..Although biological effects were observed only at relatively high concentrations, this chemical series provides an excellent starting point for drug optimization and further development... - Strategies for targeting the multidrug resistance-1 (MDR1)/P-gp transporter in human malignanciesDaruka Mahadevan
University of Arizona Cancer Center, Tucson, AZ 85724, USA. dmahadevan @azcc.arizona.edu
Curr Cancer Drug Targets 5:445-55. 2005.... - NSC348884, a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis in human cancer cellsW Qi
Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA
Oncogene 27:4210-20. 2008..The data together show that NSC348884 is an SMI of NPM oligomer formation, upregulates p53, induces apoptosis and synergizes with chemotherapy. Hence, an SMI to NPM may be a useful approach to anticancer therapy... - Specific inhibition of the Akt1 pleckstrin homology domain by D-3-deoxy-phosphatidyl-myo-inositol analoguesEmmanuelle J Meuillet
Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724, USA
Mol Cancer Ther 2:389-99. 2003..This study shows that the DPIs are a novel class of growth inhibitory agents with a novel mechanism of action through binding to the PH domain of Akt and inhibition of Akt activation... - Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN's tumor suppressor activityEmmanuelle J Meuillet
Arizona Cancer Center, University of Arizona, 1515 N Campbell Blvd, Tucson, AZ 85724, USA
Arch Biochem Biophys 429:123-33. 2004..The results of the study suggest that the increased levels of Trx-1 in human tumors could lead to functional inhibition of PTEN tumor suppressor activity providing an additional mechanism for tumorigenesis with loss of PTEN activity... - Amino acid changes in Drosophila alphaPS2betaPS integrins that affect ligand affinityThomas A Bunch
Department of Molecular and Cellular Biology, Arizona Cancer Center, Tucson, Arizona 85724, USA
J Biol Chem 281:5050-7. 2006..These studies establish a means to evaluate mechanisms and consequences of integrin affinity modulation in a tractable model genetic system... - An orally active small molecule TGF-beta receptor I antagonist inhibits the growth of metastatic murine breast cancerMatthew P Rausch
Department of Immunobiology, University of Arizona, Tucson, AZ 85724, USA
Anticancer Res 29:2099-109. 2009..The purpose of this study was to investigate the efficacy of SM16, a novel small molecule ALK5 kinase inhibitor, to treat a highly metastatic, TGF-beta-producing murine mammary carcinoma (4T1)... - Modulation of ligand binding by alternative splicing of the alphaPS2 integrin subunitThomas A Bunch
Department of Molecular and Cellular Biology, Arizona Cancer Center, 1515 N Campbell Ave, Tucson, Arizona 85724, USA
J Cell Biochem 102:211-23. 2007..These results may have relevance for vertebrate alpha6 and alpha7, which are alternatively spliced at the same site... - Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphomaWenqing Qi
Arizona Cancer Center, University of Arizona, 1515 N Campbell Avenue, Tucson, AZ 85724, USA
Biochem Pharmacol 81:881-90. 2011..Together, our results suggest that MLN8237 plus docetaxel may represent a novel therapeutic strategy that could be evaluated in early phase trials in relapsed/refractory aggressive B-cell NHL... - Design and activity of a murine and humanized anti-CEACAM6 single-chain variable fragment in the treatment of pancreatic cancerChristopher J Riley
Arizona Cancer Center, Tucson, AZ 85724, USA
Cancer Res 69:1933-40. 2009..Collectively, our results have important implications for the development of novel antibody-based therapies against CEACAM6 in PDA... - Monoclonal antibody therapies targeting pancreatic ductal adenocarcinomaKevin Engelhardt
Arizona Cancer Center, Tucson, AZ 85724, USA
Curr Drug Discov Technol 3:231-43. 2006.... - Translational advances and novel therapies for pancreatic ductal adenocarcinoma: hope or hype?Sreenivasa Chandana
Michigan State University, Department of Medicine, East Lansing, MI, USA
Expert Rev Mol Med 11:e34. 2009..Here we summarise current knowledge and areas where the field is advancing, and give our opinion on the research direction the field should be focusing on to better deliver promising therapies for our patients... - Variation in cytotoxic T-lymphocyte responses to peptides derived from tyrosinase-related protein-2Cheryl E Myers
Department of Immunobiology, University of Arizona, Life Sciences North, Tucson, AZ 85724, USA
Hum Immunol 69:24-31. 2008..Our results may partially explain why some patients have better clinical responses to peptide-based immunotherapy, whereas others respond poorly... - Mapping of the active site of glutamate carboxypeptidase II by site-directed mutagenesisPetra Mlcochova
Gilead Sciences and IOCB Research Centre, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic
FEBS J 274:4731-41. 2007.... - Will MDR-1/P-gp modulators provide clinical benefit in hematologic malignancies?Daruka Mahadevan
Leuk Res 30:1077-8. 2006 - Actin microfilament aggregation induced by withaferin A is mediated by annexin IIRyan R Falsey
Nat Chem Biol 2:33-8. 2006.... - Efficacy of lenalidomide in myelodysplastic syndromesAlan List
Department of Interdisciplinary Oncology, University of South Florida and the H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9497, USA
N Engl J Med 352:549-57. 2005..In patients with myelodysplastic syndromes and symptomatic anemia, we evaluated the safety and hematologic activity of lenalidomide, a novel analogue of thalidomide...